Kooperativer Bibliotheksverbund

UID:

Format: 1 online resource (292 pages)

ISBN: 9780128204184

Content: Nicotinic Acetylcholine Receptors in Health and Disease provides the latest information Nicotinic acetylcholine receptors (nAChRs), which are involved in numerous diseases, including Alzheimer's, Parkinson's, and schizophrenia, and are important potential translational targets for treatment of these diseases, as well as therapy for addiction. This book focuses on the roles and function of nAChRs inside and outside of the nervous system, with an emphasis on translational implications and future prospects for the treatment of numerous disorders. This greater understanding of the basic neurobiology and clinical roles of nAChRs provides important insights for future clinical treatments of many major disorders. Describes the roles, expression and function of nicotinic receptors Includes receptor involvement, both inside and outside the nervous system Details nicotinic receptor involvement in Alzheimer's, Parkinson's, Cancer, Schizophrenia, and more Emphasizes future treatment prospects of disorders via modulation of nAChR signaling.

Note: Intro -- Nicotinic Acetylcholine Receptors in Health and Disease -- Copyright -- Dedication -- Contents -- About the author -- Preface -- Chapter One: nAChR structure -- 1.1. Early structural studies on muscle and Torpedo nAChRs -- 1.2. Diversity of neuronal nAChRs -- 1.3. Structure of individual nAChR subunits -- 1.3.1. Extracellular domain (ECD) -- 1.3.2. Channel structure -- 1.3.3. Intracellular domains -- References -- Chapter Two: Neuronal nAChR localization, subtype diversity, and evolution -- 2.1. Subtype diversity -- 2.2. Subunit genes -- 2.3. Subtype assemblies -- 2.4. Subtypes present in vivo -- 2.5. Regional localization -- 2.6. Cellular localization -- 2.7. Summary -- References -- Further reading -- Chapter Three: Function and pharmacology of neuronal nAChRs -- 3.1. Introduction -- 3.2. Function -- 3.3. Pharmacology overview -- 3.4. Agonists -- 3.4.1. Acetylcholine -- 3.4.2. Nicotine -- 3.4.3. Epibatidine -- 3.4.4. Cytisine -- 3.4.5. Varenicline -- 3.4.6. ABT-418 -- 3.4.7. ABT-594 -- 3.4.8. ABT-126 -- 3.4.9. GTS-21 (DXMBA) -- 3.4.10. Sazetidine-A -- 3.4.11. Choline -- 3.5. Antagonists -- 3.5.1. Conotoxins -- 3.5.2. Mecamylamine -- 3.5.3. Dihydro-β-erythroidine (DHβE) -- 3.5.4. Methyllycaconitine (MLA) -- 3.5.5. Alpha Bungarotoxin (α-Bgt) -- 3.6. Allosteric modulators -- 3.6.1. Positive allosteric modulators (PAM) -- 3.6.1.1. NS-1738 -- 3.6.1.2. PNU-120596 -- 3.6.1.3. 3a,4,5,9b-Tetrahydro-4-(1-naphthalenyl)-3H-cyclopentan[c]quinoline-8-sulfonamide (TQS) -- 3.6.1.4. NS9283 -- 3.6.1.5. Desformylflustrabromine (dFBr) -- 3.6.2. Negative allosteric modulators (NAMs) -- 3.6.3. Allosteric agonists and Ago-PAMs -- 3.6.4. Silent agonists -- 3.6.5. Endogenous modulators -- 3.7. Summary -- References -- Further reading -- Chapter Four: Nicotine addiction: The role of specific nAChR subtypes and treatments -- 4.1. Introduction. , 4.2. Nicotine metabolism -- 4.3. Presentation of nicotine addiction in humans and in animal models -- 4.4. Reward pathways for nicotine -- 4.5. Genetic involvement in nicotine addiction -- 4.6. nAChR subtypes involved in the effects of nicotine on reward and aversion -- 4.7. Pharmacotherapy for nicotine addiction -- 4.8. Other potential candidates for smoking cessation -- References -- Chapter Five: Disease associations-Alzheimers disease, schizophrenia, Parkinsons disease, autism, and cancer -- 5.1. Alzheimers disease -- 5.1.1. Background -- 5.1.2. Cholinergic role in Alzheimers disease -- 5.1.3. Amyloid beta -- 5.1.4. Interactions between amyloid beta and nAChRs -- 5.1.5. Potential therapies -- 5.1.6. Summary -- 5.2. Schizophrenia -- 5.2.1. Basics of schizophrenia -- 5.2.2. Cholinergic role in schizophrenia -- 5.2.3. nAChRs and schizophrenia -- 5.2.4. Cholinergic drugs for possible schizophrenia treatment -- 5.2.5. Summary -- 5.3. Autism -- 5.3.1. Basics of autism -- 5.3.2. Evidence for a cholinergic role in ASD -- 5.3.3. nAChRs and autism -- 5.3.4. Cholinergic approaches to treating autism -- 5.3.5. Summary -- 5.4. Parkinsons disease -- 5.4.1. Background -- 5.4.2. Cholinergic role in Parkinsons disease -- 5.4.3. Treatment using cholinergic modulation -- 5.4.4. Effects on neurodegeneration -- 5.4.5. Treatment of LIDs -- 5.4.6. Improvement in motor symptoms -- 5.4.7. Summary -- 5.5. Cancer -- 5.5.1. Introduction -- 5.5.2. Nicotinic cholinergic systems and nAChRs are present in normal and cancerous lung and pancreas -- 5.5.3. Mechanisms of nicotine action in lung and pancreatic cancer -- 5.5.4. Possible treatment by modulation of cholinergic signaling and nAChRs -- References -- Chapter Six: Role of neuronal nAChRs in normal development and plasticity. , 6.1. Acetylcholine and receptors are present and function before and early in nervous system development -- 6.2. Timing and location of nAChR subtypes during development -- 6.3. The role of nAChRs in specific developmental events -- 6.3.1. Development of retinal waves -- 6.3.2. Development of inhibitory GABAA-mediated signaling -- 6.3.3. Myelination and differentiation of oligodendrocytes -- 6.3.4. Cortical development -- 6.3.5. Glutamatergic synapse development -- 6.4. Additional developmental effects -- 6.4.1. Cholinergic role in motor circuit development -- 6.4.2. Tooth development -- 6.4.3. Adrenal gland development -- 6.4.4. Cochlear inner hair cell (IHC) development -- References -- Chapter Seven: Developmental, epigenetic, and possible transgenerational effects of smoking and vaping -- 7.1. Effects of maternal nicotine exposure on various organ systems -- 7.2. Nervous system effects of prenatal nicotine exposure -- 7.3. Nervous system effects of adolescent nicotine exposure -- 7.4. Role of specific nAChR subtypes and possible mechanisms -- 7.5. Vaping: Prenatal and adolescent effects -- 7.6. Epigenetic effects of nicotine exposure -- 7.7. Intergenerational and transgenerational effects -- References -- Chapter Eight: Expression and function of nonneuronal nAChRs -- 8.1. Expression of nAChRs and a cholinergic system in nonneuronal cells -- 8.2. Nonneuronal cholinergic system overview -- 8.3. Cholinergic system in immune cells -- 8.3.1. Cholinergic antiinflammatory network -- 8.3.2. Nicotinic cholinergic signaling in T cells and mast cells -- 8.3.3. Therapeutic modulation of α7 nAChRs in immune function -- 8.3.4. Immune summary -- 8.4. Cholinergic system in skin cells -- 8.4.1. Nicotine effects on skin -- 8.4.2. nAChR functions in skin -- 8.4.3. Potential mechanisms of action in skin cells -- 8.4.4. Skin summary -- References. , Chapter Nine: Regulation of nAChR expression: Posttranscriptional regulation of nAChRs -- 9.1. Assembly of NMJ nAChRs -- 9.2. Assembly and trafficking of neuronal nAChRs -- 9.3. NACHO -- 9.4. 14-3-3η and adenomatous polyposis coli (APC) -- 9.5. ly6/uPAR prototoxins -- 9.5.1. Lynx1(ly6/ neurotoxin 1) -- 9.5.2. Lynx 2 (ly6/neurotoxin 2) -- 9.5.3. Secreted Ly-6/uPAR-related proteins (SLURPs) -- 9.6. Menthol -- 9.7. Upregulation by nicotine: An important role in addiction -- 9.8. MicroRNA (miRNA) -- References -- Chapter Ten: Nonmammalian models for studying nAChRs -- zebrafish, fruit fly, and worm. What have we learned? -- 10.1. Danio rerio (D. rerio) -- 10.1.1. Biology and nervous system -- 10.1.2. nAChRs Genes -- 10.1.3. Localization and expression -- 10.1.4. Pharmacology of zebrafish nAChRs -- 10.1.5. Zebrafish nAChRs in development -- 10.1.6. Applications of zebrafish for behavioral studies -- 10.1.6.1. Anxiety -- 10.1.6.2. CPP -- 10.1.6.3. Withdrawal -- 10.1.6.4. Epigenetics -- 10.1.6.5. Transgenerational assays -- 10.1.6.6. Learning and memory -- 10.1.6.7. Other behaviors -- 10.1.7. Utility of zebrafish for high-throughput screening (HTS) of cholinergic drugs -- 10.2. Caenorhabditis elegans (C. elegans) -- 10.2.1. Ric-3 and chaperoning -- 10.2.2. Behavior -- 10.2.3. Epigenetics -- 10.3. Drosophila melanogaster (D. melanogaster) -- 10.3.1. Biogenic amine signaling and Parkinsons disease -- 10.3.2. Mechanisms of insecticide action -- References -- Index.

Additional Edition: Print version: Boyd, R. Thomas Nicotinic Acetylcholine Receptors in Health and Disease San Diego : Elsevier Science & Technology,c2023 ISBN 9780128199589

Language: English

UID:

Format: 1 online resource (292 pages)

ISBN: 9780128204184

Content: Nicotinic Acetylcholine Receptors in Health and Disease provides the latest information Nicotinic acetylcholine receptors (nAChRs), which are involved in numerous diseases, including Alzheimer's, Parkinson's, and schizophrenia, and are important potential translational targets for treatment of these diseases, as well as therapy for addiction. This book focuses on the roles and function of nAChRs inside and outside of the nervous system, with an emphasis on translational implications and future prospects for the treatment of numerous disorders. This greater understanding of the basic neurobiology and clinical roles of nAChRs provides important insights for future clinical treatments of many major disorders. Describes the roles, expression and function of nicotinic receptors Includes receptor involvement, both inside and outside the nervous system Details nicotinic receptor involvement in Alzheimer's, Parkinson's, Cancer, Schizophrenia, and more Emphasizes future treatment prospects of disorders via modulation of nAChR signaling.

Note: Intro -- Nicotinic Acetylcholine Receptors in Health and Disease -- Copyright -- Dedication -- Contents -- About the author -- Preface -- Chapter One: nAChR structure -- 1.1. Early structural studies on muscle and Torpedo nAChRs -- 1.2. Diversity of neuronal nAChRs -- 1.3. Structure of individual nAChR subunits -- 1.3.1. Extracellular domain (ECD) -- 1.3.2. Channel structure -- 1.3.3. Intracellular domains -- References -- Chapter Two: Neuronal nAChR localization, subtype diversity, and evolution -- 2.1. Subtype diversity -- 2.2. Subunit genes -- 2.3. Subtype assemblies -- 2.4. Subtypes present in vivo -- 2.5. Regional localization -- 2.6. Cellular localization -- 2.7. Summary -- References -- Further reading -- Chapter Three: Function and pharmacology of neuronal nAChRs -- 3.1. Introduction -- 3.2. Function -- 3.3. Pharmacology overview -- 3.4. Agonists -- 3.4.1. Acetylcholine -- 3.4.2. Nicotine -- 3.4.3. Epibatidine -- 3.4.4. Cytisine -- 3.4.5. Varenicline -- 3.4.6. ABT-418 -- 3.4.7. ABT-594 -- 3.4.8. ABT-126 -- 3.4.9. GTS-21 (DXMBA) -- 3.4.10. Sazetidine-A -- 3.4.11. Choline -- 3.5. Antagonists -- 3.5.1. Conotoxins -- 3.5.2. Mecamylamine -- 3.5.3. Dihydro-β-erythroidine (DHβE) -- 3.5.4. Methyllycaconitine (MLA) -- 3.5.5. Alpha Bungarotoxin (α-Bgt) -- 3.6. Allosteric modulators -- 3.6.1. Positive allosteric modulators (PAM) -- 3.6.1.1. NS-1738 -- 3.6.1.2. PNU-120596 -- 3.6.1.3. 3a,4,5,9b-Tetrahydro-4-(1-naphthalenyl)-3H-cyclopentan[c]quinoline-8-sulfonamide (TQS) -- 3.6.1.4. NS9283 -- 3.6.1.5. Desformylflustrabromine (dFBr) -- 3.6.2. Negative allosteric modulators (NAMs) -- 3.6.3. Allosteric agonists and Ago-PAMs -- 3.6.4. Silent agonists -- 3.6.5. Endogenous modulators -- 3.7. Summary -- References -- Further reading -- Chapter Four: Nicotine addiction: The role of specific nAChR subtypes and treatments -- 4.1. Introduction. , 4.2. Nicotine metabolism -- 4.3. Presentation of nicotine addiction in humans and in animal models -- 4.4. Reward pathways for nicotine -- 4.5. Genetic involvement in nicotine addiction -- 4.6. nAChR subtypes involved in the effects of nicotine on reward and aversion -- 4.7. Pharmacotherapy for nicotine addiction -- 4.8. Other potential candidates for smoking cessation -- References -- Chapter Five: Disease associations-Alzheimers disease, schizophrenia, Parkinsons disease, autism, and cancer -- 5.1. Alzheimers disease -- 5.1.1. Background -- 5.1.2. Cholinergic role in Alzheimers disease -- 5.1.3. Amyloid beta -- 5.1.4. Interactions between amyloid beta and nAChRs -- 5.1.5. Potential therapies -- 5.1.6. Summary -- 5.2. Schizophrenia -- 5.2.1. Basics of schizophrenia -- 5.2.2. Cholinergic role in schizophrenia -- 5.2.3. nAChRs and schizophrenia -- 5.2.4. Cholinergic drugs for possible schizophrenia treatment -- 5.2.5. Summary -- 5.3. Autism -- 5.3.1. Basics of autism -- 5.3.2. Evidence for a cholinergic role in ASD -- 5.3.3. nAChRs and autism -- 5.3.4. Cholinergic approaches to treating autism -- 5.3.5. Summary -- 5.4. Parkinsons disease -- 5.4.1. Background -- 5.4.2. Cholinergic role in Parkinsons disease -- 5.4.3. Treatment using cholinergic modulation -- 5.4.4. Effects on neurodegeneration -- 5.4.5. Treatment of LIDs -- 5.4.6. Improvement in motor symptoms -- 5.4.7. Summary -- 5.5. Cancer -- 5.5.1. Introduction -- 5.5.2. Nicotinic cholinergic systems and nAChRs are present in normal and cancerous lung and pancreas -- 5.5.3. Mechanisms of nicotine action in lung and pancreatic cancer -- 5.5.4. Possible treatment by modulation of cholinergic signaling and nAChRs -- References -- Chapter Six: Role of neuronal nAChRs in normal development and plasticity. , 6.1. Acetylcholine and receptors are present and function before and early in nervous system development -- 6.2. Timing and location of nAChR subtypes during development -- 6.3. The role of nAChRs in specific developmental events -- 6.3.1. Development of retinal waves -- 6.3.2. Development of inhibitory GABAA-mediated signaling -- 6.3.3. Myelination and differentiation of oligodendrocytes -- 6.3.4. Cortical development -- 6.3.5. Glutamatergic synapse development -- 6.4. Additional developmental effects -- 6.4.1. Cholinergic role in motor circuit development -- 6.4.2. Tooth development -- 6.4.3. Adrenal gland development -- 6.4.4. Cochlear inner hair cell (IHC) development -- References -- Chapter Seven: Developmental, epigenetic, and possible transgenerational effects of smoking and vaping -- 7.1. Effects of maternal nicotine exposure on various organ systems -- 7.2. Nervous system effects of prenatal nicotine exposure -- 7.3. Nervous system effects of adolescent nicotine exposure -- 7.4. Role of specific nAChR subtypes and possible mechanisms -- 7.5. Vaping: Prenatal and adolescent effects -- 7.6. Epigenetic effects of nicotine exposure -- 7.7. Intergenerational and transgenerational effects -- References -- Chapter Eight: Expression and function of nonneuronal nAChRs -- 8.1. Expression of nAChRs and a cholinergic system in nonneuronal cells -- 8.2. Nonneuronal cholinergic system overview -- 8.3. Cholinergic system in immune cells -- 8.3.1. Cholinergic antiinflammatory network -- 8.3.2. Nicotinic cholinergic signaling in T cells and mast cells -- 8.3.3. Therapeutic modulation of α7 nAChRs in immune function -- 8.3.4. Immune summary -- 8.4. Cholinergic system in skin cells -- 8.4.1. Nicotine effects on skin -- 8.4.2. nAChR functions in skin -- 8.4.3. Potential mechanisms of action in skin cells -- 8.4.4. Skin summary -- References. , Chapter Nine: Regulation of nAChR expression: Posttranscriptional regulation of nAChRs -- 9.1. Assembly of NMJ nAChRs -- 9.2. Assembly and trafficking of neuronal nAChRs -- 9.3. NACHO -- 9.4. 14-3-3η and adenomatous polyposis coli (APC) -- 9.5. ly6/uPAR prototoxins -- 9.5.1. Lynx1(ly6/ neurotoxin 1) -- 9.5.2. Lynx 2 (ly6/neurotoxin 2) -- 9.5.3. Secreted Ly-6/uPAR-related proteins (SLURPs) -- 9.6. Menthol -- 9.7. Upregulation by nicotine: An important role in addiction -- 9.8. MicroRNA (miRNA) -- References -- Chapter Ten: Nonmammalian models for studying nAChRs -- zebrafish, fruit fly, and worm. What have we learned? -- 10.1. Danio rerio (D. rerio) -- 10.1.1. Biology and nervous system -- 10.1.2. nAChRs Genes -- 10.1.3. Localization and expression -- 10.1.4. Pharmacology of zebrafish nAChRs -- 10.1.5. Zebrafish nAChRs in development -- 10.1.6. Applications of zebrafish for behavioral studies -- 10.1.6.1. Anxiety -- 10.1.6.2. CPP -- 10.1.6.3. Withdrawal -- 10.1.6.4. Epigenetics -- 10.1.6.5. Transgenerational assays -- 10.1.6.6. Learning and memory -- 10.1.6.7. Other behaviors -- 10.1.7. Utility of zebrafish for high-throughput screening (HTS) of cholinergic drugs -- 10.2. Caenorhabditis elegans (C. elegans) -- 10.2.1. Ric-3 and chaperoning -- 10.2.2. Behavior -- 10.2.3. Epigenetics -- 10.3. Drosophila melanogaster (D. melanogaster) -- 10.3.1. Biogenic amine signaling and Parkinsons disease -- 10.3.2. Mechanisms of insecticide action -- References -- Index.

Additional Edition: Print version: Boyd, R. Thomas Nicotinic Acetylcholine Receptors in Health and Disease San Diego : Elsevier Science & Technology,c2023 ISBN 9780128199589

Language: English

UID:

Format: 1 online resource (292 pages)

ISBN: 9780128204184

Content: Nicotinic Acetylcholine Receptors in Health and Disease provides the latest information Nicotinic acetylcholine receptors (nAChRs), which are involved in numerous diseases, including Alzheimer's, Parkinson's, and schizophrenia, and are important potential translational targets for treatment of these diseases, as well as therapy for addiction. This book focuses on the roles and function of nAChRs inside and outside of the nervous system, with an emphasis on translational implications and future prospects for the treatment of numerous disorders. This greater understanding of the basic neurobiology and clinical roles of nAChRs provides important insights for future clinical treatments of many major disorders. Describes the roles, expression and function of nicotinic receptors Includes receptor involvement, both inside and outside the nervous system Details nicotinic receptor involvement in Alzheimer's, Parkinson's, Cancer, Schizophrenia, and more Emphasizes future treatment prospects of disorders via modulation of nAChR signaling.

Note: Intro -- Nicotinic Acetylcholine Receptors in Health and Disease -- Copyright -- Dedication -- Contents -- About the author -- Preface -- Chapter One: nAChR structure -- 1.1. Early structural studies on muscle and Torpedo nAChRs -- 1.2. Diversity of neuronal nAChRs -- 1.3. Structure of individual nAChR subunits -- 1.3.1. Extracellular domain (ECD) -- 1.3.2. Channel structure -- 1.3.3. Intracellular domains -- References -- Chapter Two: Neuronal nAChR localization, subtype diversity, and evolution -- 2.1. Subtype diversity -- 2.2. Subunit genes -- 2.3. Subtype assemblies -- 2.4. Subtypes present in vivo -- 2.5. Regional localization -- 2.6. Cellular localization -- 2.7. Summary -- References -- Further reading -- Chapter Three: Function and pharmacology of neuronal nAChRs -- 3.1. Introduction -- 3.2. Function -- 3.3. Pharmacology overview -- 3.4. Agonists -- 3.4.1. Acetylcholine -- 3.4.2. Nicotine -- 3.4.3. Epibatidine -- 3.4.4. Cytisine -- 3.4.5. Varenicline -- 3.4.6. ABT-418 -- 3.4.7. ABT-594 -- 3.4.8. ABT-126 -- 3.4.9. GTS-21 (DXMBA) -- 3.4.10. Sazetidine-A -- 3.4.11. Choline -- 3.5. Antagonists -- 3.5.1. Conotoxins -- 3.5.2. Mecamylamine -- 3.5.3. Dihydro-β-erythroidine (DHβE) -- 3.5.4. Methyllycaconitine (MLA) -- 3.5.5. Alpha Bungarotoxin (α-Bgt) -- 3.6. Allosteric modulators -- 3.6.1. Positive allosteric modulators (PAM) -- 3.6.1.1. NS-1738 -- 3.6.1.2. PNU-120596 -- 3.6.1.3. 3a,4,5,9b-Tetrahydro-4-(1-naphthalenyl)-3H-cyclopentan[c]quinoline-8-sulfonamide (TQS) -- 3.6.1.4. NS9283 -- 3.6.1.5. Desformylflustrabromine (dFBr) -- 3.6.2. Negative allosteric modulators (NAMs) -- 3.6.3. Allosteric agonists and Ago-PAMs -- 3.6.4. Silent agonists -- 3.6.5. Endogenous modulators -- 3.7. Summary -- References -- Further reading -- Chapter Four: Nicotine addiction: The role of specific nAChR subtypes and treatments -- 4.1. Introduction. , 4.2. Nicotine metabolism -- 4.3. Presentation of nicotine addiction in humans and in animal models -- 4.4. Reward pathways for nicotine -- 4.5. Genetic involvement in nicotine addiction -- 4.6. nAChR subtypes involved in the effects of nicotine on reward and aversion -- 4.7. Pharmacotherapy for nicotine addiction -- 4.8. Other potential candidates for smoking cessation -- References -- Chapter Five: Disease associations-Alzheimers disease, schizophrenia, Parkinsons disease, autism, and cancer -- 5.1. Alzheimers disease -- 5.1.1. Background -- 5.1.2. Cholinergic role in Alzheimers disease -- 5.1.3. Amyloid beta -- 5.1.4. Interactions between amyloid beta and nAChRs -- 5.1.5. Potential therapies -- 5.1.6. Summary -- 5.2. Schizophrenia -- 5.2.1. Basics of schizophrenia -- 5.2.2. Cholinergic role in schizophrenia -- 5.2.3. nAChRs and schizophrenia -- 5.2.4. Cholinergic drugs for possible schizophrenia treatment -- 5.2.5. Summary -- 5.3. Autism -- 5.3.1. Basics of autism -- 5.3.2. Evidence for a cholinergic role in ASD -- 5.3.3. nAChRs and autism -- 5.3.4. Cholinergic approaches to treating autism -- 5.3.5. Summary -- 5.4. Parkinsons disease -- 5.4.1. Background -- 5.4.2. Cholinergic role in Parkinsons disease -- 5.4.3. Treatment using cholinergic modulation -- 5.4.4. Effects on neurodegeneration -- 5.4.5. Treatment of LIDs -- 5.4.6. Improvement in motor symptoms -- 5.4.7. Summary -- 5.5. Cancer -- 5.5.1. Introduction -- 5.5.2. Nicotinic cholinergic systems and nAChRs are present in normal and cancerous lung and pancreas -- 5.5.3. Mechanisms of nicotine action in lung and pancreatic cancer -- 5.5.4. Possible treatment by modulation of cholinergic signaling and nAChRs -- References -- Chapter Six: Role of neuronal nAChRs in normal development and plasticity. , 6.1. Acetylcholine and receptors are present and function before and early in nervous system development -- 6.2. Timing and location of nAChR subtypes during development -- 6.3. The role of nAChRs in specific developmental events -- 6.3.1. Development of retinal waves -- 6.3.2. Development of inhibitory GABAA-mediated signaling -- 6.3.3. Myelination and differentiation of oligodendrocytes -- 6.3.4. Cortical development -- 6.3.5. Glutamatergic synapse development -- 6.4. Additional developmental effects -- 6.4.1. Cholinergic role in motor circuit development -- 6.4.2. Tooth development -- 6.4.3. Adrenal gland development -- 6.4.4. Cochlear inner hair cell (IHC) development -- References -- Chapter Seven: Developmental, epigenetic, and possible transgenerational effects of smoking and vaping -- 7.1. Effects of maternal nicotine exposure on various organ systems -- 7.2. Nervous system effects of prenatal nicotine exposure -- 7.3. Nervous system effects of adolescent nicotine exposure -- 7.4. Role of specific nAChR subtypes and possible mechanisms -- 7.5. Vaping: Prenatal and adolescent effects -- 7.6. Epigenetic effects of nicotine exposure -- 7.7. Intergenerational and transgenerational effects -- References -- Chapter Eight: Expression and function of nonneuronal nAChRs -- 8.1. Expression of nAChRs and a cholinergic system in nonneuronal cells -- 8.2. Nonneuronal cholinergic system overview -- 8.3. Cholinergic system in immune cells -- 8.3.1. Cholinergic antiinflammatory network -- 8.3.2. Nicotinic cholinergic signaling in T cells and mast cells -- 8.3.3. Therapeutic modulation of α7 nAChRs in immune function -- 8.3.4. Immune summary -- 8.4. Cholinergic system in skin cells -- 8.4.1. Nicotine effects on skin -- 8.4.2. nAChR functions in skin -- 8.4.3. Potential mechanisms of action in skin cells -- 8.4.4. Skin summary -- References. , Chapter Nine: Regulation of nAChR expression: Posttranscriptional regulation of nAChRs -- 9.1. Assembly of NMJ nAChRs -- 9.2. Assembly and trafficking of neuronal nAChRs -- 9.3. NACHO -- 9.4. 14-3-3η and adenomatous polyposis coli (APC) -- 9.5. ly6/uPAR prototoxins -- 9.5.1. Lynx1(ly6/ neurotoxin 1) -- 9.5.2. Lynx 2 (ly6/neurotoxin 2) -- 9.5.3. Secreted Ly-6/uPAR-related proteins (SLURPs) -- 9.6. Menthol -- 9.7. Upregulation by nicotine: An important role in addiction -- 9.8. MicroRNA (miRNA) -- References -- Chapter Ten: Nonmammalian models for studying nAChRs -- zebrafish, fruit fly, and worm. What have we learned? -- 10.1. Danio rerio (D. rerio) -- 10.1.1. Biology and nervous system -- 10.1.2. nAChRs Genes -- 10.1.3. Localization and expression -- 10.1.4. Pharmacology of zebrafish nAChRs -- 10.1.5. Zebrafish nAChRs in development -- 10.1.6. Applications of zebrafish for behavioral studies -- 10.1.6.1. Anxiety -- 10.1.6.2. CPP -- 10.1.6.3. Withdrawal -- 10.1.6.4. Epigenetics -- 10.1.6.5. Transgenerational assays -- 10.1.6.6. Learning and memory -- 10.1.6.7. Other behaviors -- 10.1.7. Utility of zebrafish for high-throughput screening (HTS) of cholinergic drugs -- 10.2. Caenorhabditis elegans (C. elegans) -- 10.2.1. Ric-3 and chaperoning -- 10.2.2. Behavior -- 10.2.3. Epigenetics -- 10.3. Drosophila melanogaster (D. melanogaster) -- 10.3.1. Biogenic amine signaling and Parkinsons disease -- 10.3.2. Mechanisms of insecticide action -- References -- Index.

Additional Edition: Print version: Boyd, R. Thomas Nicotinic Acetylcholine Receptors in Health and Disease San Diego : Elsevier Science & Technology,c2023 ISBN 9780128199589

Language: English